Current issues of RNAi therapeutics delivery and development

Journal of Controlled Release

Volumn 195, Issue , 2014, Pages 49-54

  Haussecker, D ^a  

^a NONE   (Germany)

Author keywords

Delivery; RNAi therapeutics; Synthetic RNAi triggers

Indexed keywords

DELIVERY; RNAI THERAPEUTICS; SYNTHETIC RNAI TRIGGERS;

LIPID NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MICRORNA;

ARTICLE; CIRCULATION TIME; ENDOTHELIUM CELL; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; KIDNEY CELL; LIVER; LIVER CELL; NONHUMAN; PHAGOCYTE; RESPIRATORY EPITHELIUM; RETINA CELL; RNA DELIVERY; RNA INTERFERENCE; SKIN CELL; ANIMAL; CELL MEMBRANE; HUMAN; METABOLISM;

ANIMALS; CELL MEMBRANE; HUMANS; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84908564426     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.07.056     Document Type: Article

References (50)

1. D. Haussecker The business of RNAi Therapeutics Hum. Gene Ther. 19 2008 451
2. K.T. Love Lipid-like materials for low-dose, in vivo gene silencing Proc. Natl. Acad. Sci. 107 2010 1864
3. V.N. Kim Biogenesis of small RNAs in animals Nat. Rev. Mol. Cell Biol. 10 2009 126
4. N. Vaish Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs Nucleic Acids Res. 39 2011 1823
5. W.F. Lima Single-stranded siRNAs activate RNAi in animals Cell 150 2012 883
6. F. Czauderna Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells Nucleic Acids Res. 31 2003 2705
7. D.V. Morrissey Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat. Biotechnol. 23 2005 1002
8. P.Y. Chen Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity RNA 14 2008 263
9. M. Byrne Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye J. Ocul. Pharmacol. Ther. 29 2013 855
10. A.A. Raoof Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate J. Pharm. Sci. 93 2004 1431
11. B. Ballarin-Gonzalez Protection and systemic translocation of siRNA following oral administration of chitosan/siRNA nanoparticles Mol. Ther. Nucleic Acids 2 2013 e76
12. M. Aouadi Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation Nature 458 2009 1180
13. http://www.alnylam.com/web/wp-content/uploads/2013/10/ALNY-ConjugateUpdate-OTS2013.pdf
14. C.M. Paulos Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery Mol. Pharmacol. 66 2004 1406
15. http://www.alnylam.com/web/wp-content/uploads/2013/09/ALN-TTRsc-PhI-HFSA-Poster-Sep2013.pdf
16. C.I. Wooddell Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol. Ther. 21 2013 973
17. S.C. Wong Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo Nucleic Acid Ther. 22 2012 380
18. http://files.shareholder.com/downloads/ABEA-50QJTB/2628241206x0x695629/1af9ba39-fa32-4d8c-b45a-971ed117f1b8/Webinar-Slides4Web.pdf
19. T. Coelho Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 369 2013 819
20. http://www.alnylam.com/web/wp-content/uploads/2013/11/ALNY-ISFAP-ALN-TTRprogram-Nov2013.pdf
21. J. Tabernero First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Cancer Discov. 3 2013 406
22. C. Coch A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotide siRNA PLoS One 8 2013 e71057
23. I. MacLachlan, and P. Cullis Diffusible-PEG-lipid stabilized plasmid lipid particles Adv. Genet. 53 2009 157
24. B.A. Molitoris siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury J. Am. Soc. Nephrol. 20 2008 1754
25. S. Lee Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo Nucleic Acids Res. 37 2009 e145
26. T.I. Novobrantseva Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells Mol. Ther. Nucleic Acids 1 2012 e4
27. D. Peer A daunting task: manipulating leukocyte function with RNAi Immunol. Rev. 253 2013 185
28. M. Aleku Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression Cancer Res. 68 2008 9788
29. V. Fehring Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC Mol. Ther. 22 2014 811
30. R.J. Boado Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor Mol. Pharm. 7 2010 237
31. J. Niewoehner Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle Neuron 81 2014 49
32. L. Li Tumor vasculature is a key determinant for the efficacy of nanoparticle-mediated siRNA delivery Gene Ther. 19 2012 775
33. T. Teesalu C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration Proc. Natl. Acad. Sci. U. S. A. 106 2009 16157
34. K. Huang Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo ACS Nano 6 2012 4483
35. B.R. Meade Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides Adv. Drug Deliv. Rev. 59 2007 134
36. D.B. Rozema Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc. Natl. Acad. Sci. U. S. A. 104 2007 12982
37. A. Akinc Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanism Mol. Ther. 18 2010 1357
38. G. Sahav Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling Nat. Biotechnol. 31 2013 653
39. M. Butler Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice J. Pharmacol. Exp. Ther. 292 2000 489
40. S.C. Semple Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172
41. O. Boussif A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proc. Natl. Acad. Sci. U. S. A. 92 1995 7297
42. J. Zhou Selection, characterization and application of new RNA HIV gp120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells Nucleic Acids Res. 37 2009 3094
43. J.P. DeVincenzo The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses Antivir. Ther. 17 2012 213
44. R.P. Hickerson Gene silencing in skin after deposition of self-delivery siRNA with a motorized microneedle array device Mol. Ther. Nucleic Acids 2 2013 e129
45. S.M. Elbashir Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494
46. M. Aleku Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression Cancer Res. 68 2008 9788
47. D. Haussecker The business of RNAi Therapeutics in 2012 Mol. Ther. Nucleic Acids 1 2012 e8
48. A.D. Judge Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA Nat. Biotechnol. 23 2005 457
49. http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=534353
50. http://www.alnylam.com/web/assets/Roundtable-ESC-GalNAc-Conjugates-072214.pdf